Alogliptin
A DPP-4 inhibitor that enhances the body's natural incretin hormones to stimulate insulin secretion and reduce glucagon release in response to meals, lowering blood sugar in adults with type 2 diabetes. It has cardiovascular safety data showing it does not increase the risk of heart failure.
Masse moléculaire
339,4000 g/mol
LogP
0,60
TPSA
93,70 Ų
Règle des 5 de Lipinski
Conforme
Aires thérapeutiques
Mécanisme d'action
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Structure 2D
Cite this structure
Embed this structure
SMILES
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O
InChI
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
Molecular Formula
C18H21N5O2
HBD / HBA
1 / 5
Liaisons Rotatives
3
Atomes Lourds
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A DPP-4 inhibitor that enhances the body's natural incretin hormones to stimulate insulin secretion and reduce glucagon release in response to meals, lowering blood sugar in adults with type 2 diabetes. It has cardiovascular safety data showing it does not increase the risk of heart failure.
Inhibits dipeptidyl peptidase-4, the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, stimulating glucose-dependent insulin secretion and suppressing glucagon release.
Yes, Alogliptin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL376359. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11450633. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="alogliptin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/alogliptin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/alogliptin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/alogliptin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="alogliptin"></drugfyi-drug>